Esclerosis múltiple y fatiga

ANALES DEL SISTEMA SANITARIO DE NAVARRA

alud Pública y Administración Sanitaria

Esclerosis múltiple y fatiga
Multiple sclerosis and fatigue

P. de Castro, A. Abad, E. Bárcena, A. Rotger, J. Iriarte


Departamento de Neurología. Clínica Universitaria de Navarra. Universidad de Navarra. Pamplona

>

BIBLIOGRAFÍA

1. Tola MA, Yugueros MI, Férnandez BN, Férnandez HR. Impacto de la fatiga en la esclerosis múltiple: estudio de una serie de base poblacional en Valladolid. Rev Neurol 1998; 26: 930-933.

2. Colosimo C, Millefiorini E, Grasso MG, Vinci F, Fiorelli M, Koudriavtseva T et al. Fatigue in MS is associated with specific clinical features. Acta Neurol Scand 1995; 92: 353-355.

3. Tola MA, Yugueros MI, Fernández BN, Marco J, Gutiérrez GJ, Gómez NJ et al. Deficiencia, discapacidad y minusvalia en la esclerosis multiple: un estudio de base poblacional en Valladolid. Rev Neurol 1998; 26: 728-734.

4. Djaldetti R, Ziv I, Achiron A, Melamed E. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment. Neurology 1996; 46: 632-635.

5. Mc Alpine E, Lumsden C, Acheson E. Multiple Sclerosis. A reappraisal. Edinburgh: Churchill Livingstone 1972.

6. Kelly R. Clinical aspects of multiple sclerosis. Handbook of Neurology. 59. 1985. Amsterdam, Elsevier Science Publishers.

7. Monks J. Experiencing symptoms in chronic illness: fatigue in multiple sclerosis. Int Disabil Stud 1989; 11: 78-83.

8. Rosse RB. Fatigue in multiple sclerosis. Arch Neurol 1989; 46: 841-842.

9. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994; 21: 9-14.

10. Krupp LB, LaRocca NG, Muir Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.

11. Iriarte J, de Castro P. Propuesta de una nueva escala para la evaluación de la fatiga en pacientes con esclerosis múltiple. Neurología 1994; 9: 96-100.

12. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18 (Suppl 1): S79-83.

13. Iriarte J, Katsamakis G, de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler 1999; 5: 10-16.

14. Tesio L, Perucca L, Franchignoni FP, Battaglia MA. A short measure of balance in multiple sclerosis: validation through Rasch analysis. Funct Neurol 1997; 12: 255-265.

15. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993; 37: 753-762.

16. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999; 5: 251-259.

17. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology 1999; 52: 63-70.

18. LaRocca NG. The objective measurement of fatigue in Multiple Sclerosis. Neurology 1992; 42: 384-384.

19. Matsumoto T, Ito K, Moritani T. The relationship between anaerobic threshold and electromyographic fatigue threshold in college women. Eur J Appl Physiol 1991; 63: 1-5.

20. Brasil Neto JP, Cohen LG, Hallett M. Central fatigue as revealed by postexercise decrement of motor evoked potentials. Muscle Nerve 1994; 17: 713-719.

21. Sandyk R. Bidirectional effect of electromagnetic fields on ketanserin- induced yawning in patients with multiple sclerosis: the role of melatonin. Int J Neurosci 1996; 85: 93-99.

22. Rudick RA, Barna BP. Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue. Arch Neurol 1990; 47: 254-255.

23. Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992; 87: 76-79.

24. Mohr K, Coyle PK, Krupp LB, Doschler C. Serial immune changes in multiple sclerosis patiens under treatment for fatigue. Neurology 1992; 42(Suppl 3), 384-384.

25. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119: 225-237.

26. Iriarte J, Carreño M, de Castro P. Fatiga y afectación por sistemas funcionales en esclerosis multiple. Neurología 1996; 11: 210-215.

27. Van-der-Werf SP, Jongen PJ, Lycklama, Barkhof F, Hommes OR, Bleijenberg G. Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci 1998; 160: 164-170.

28. Sandyk R. Lack of a correlation between demyelinating plaques on MRI scan and clinical recovery in multiple sclerosis by treatment with electromagnetic fields. Int J Neurosci 1997; 89: 29-38.

29. Oligiati R, Burgunder JM, Mumenthaler M. Increased energy cost of walking in multiple sclerosis: effect of spasticity, ataxia, and weakness. Arch Phys Med Rehabil 1988; 69: 846-849.

30. Oligiati R, Jacquet J, Di Prampero PE. Energy cost of walking and exertional dyspnea in multiple sclerosis. Am Rev Respir Dis 1986; 134: 1005-1010.

31. McKay WB, Tuel SM, Sherwood AM, Stokic DS, Dimitrijevic MR. Focal depression of cortical excitability induced by fatiguing muscle contraction: a transcranial magnetic stimulation study. Exp Brain Res 1995; 105: 276-282.

32. Schubert M, Wohlfarth K, Rollnik JD, Dengler R. Walking and fatigue in multiple sclerosis: the role of the corticospinal system. Muscle Nerve 1998; 21: 1068-1070.

33. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997; 120: 299-315.

34. Latash M, Kalugina E, Nicholas J, Orpett C, Stefoski D, Davis F. Myogenic and central neurogenic factors in fatigue in multiple sclerosis. Mult Scler 1996; 1: 236-241.

35. Bakshi R, Miletich RS, Henschel K, Shaikh ZA, Janardhan V, Wasay M et al. Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients. Neurology 1999; 53: 1151-1153.

36. Mainero C, Faroni J, Gasperini C, Filippi M, Giugni E, Ciccarelli O et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol 1999; 246: 454-458.

37. Roelcke U, Kappos L, Lechner SJ, Brunnschweiler H, Huber S, Ammann W et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566-1571.

38. Vercoulen JH, Swanink CM, Galama JM, Fennis JF, Jongen PJ, Hommes OR et al. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: development of a model. J Psychosom Res 1998; 45: 507-517.

39. Vercoulen JH, Bazelmans E, Swanink CM, Fennis JF, Galama JM, Jongen PJ et al. Physical activity in chronic fatigue syndrome: assessment and its role in fatigue. J Psychiatr Res 1997; 31: 661-673.

40. Jonsson A, Dock J, Ravnborg MH. Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Acta Neurol Scand 1996; 93: 229-235.

41. Krupp LB, Sliwinski M, Masur DM, Friedberg F, Coyle PK. Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. Arch Neurol 1994; 51: 705-710.

42. McComas AJ, Miller RG, Gandevia SC. Fatigue brought on by malfunction of the central and peripheral nervous systems. Adv Exp Med Biol 1995; 384: 495-512.

43. Vaz Fragoso CA, Wirz D, Mashman J. Establishing a physiological basis to multiple sclerosis-related fatigue: a case report. Arch Phys Med Rehabil 1995; 76: 583-586.

44. Miller RG, Green AT, Moussavi RS, Carson PJ, Weiner MW. Excessive muscular fatigue in patients with spastic paraparesis. Neurology 1990; 40: 1271-1274.

45. Sharma KR, Kent Braun J, Mynhier MA, Weiner MW, Miller RG. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve 1995; 18: 1403-1411.

46. Castro MJ, Kent BJ, Miller RG, Dudley GA. Muscle fiber type-specific myofibrillar actomyosin Ca2+ ATPase activity in multiple sclerosis. Muscle Nerve 1998; 21: 547-549.

47. Hughes PJ, Kirk PF, Compston DA. Dual labelling of circulating CD8 cells in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52: 118-121.

48. Natelson BH, LaManca JJ, Denny TN, Vladutiu A, Oleske J, Hill N et al. Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis. Am J Med 1998; 105: 43S-49S.

49. Bertolone K, Coyle PK, Krupp LB, Doschler C. Cytokine correlates of fatigue in multiple sclerosis. Neurology 43, 356-356. 1993.

50. Coyle PK, Krupp LB, Doscher C, Amin K. Borrelia burgdorferi reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic. Clin Infect Dis 1994; 18 (Suppl 1): S24-7.

51. Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS et al. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol 1992; 49: 238-244.

52. Carreño, M. Tesis doctoral. Subpoblaciones linfocitarias en EM. 1998. Universidad de Navarra, Pamplona.

53. Klapps P, Seyfert S, Fischer T, Scherbaum WA. Endocrine function in multiple sclerosis. Acta Neurol Scand 1992; 85: 353-357.

54. Krupp LB, Coyle PK, Langenbach L, Doscher C, Pepper C, Klein D. Assessment of depression in multiple sclerosis patients with severe fatigue. Ann Neurol 1991; 30: 277-277.

55. Saunders J, Whitham R, Schaumann N. Sleep disturbance, fatigue and depression in multiple sclerosis. Neurology 1991; 41(Suppl 1), 320-320.

56. Taphoorn MJ, van Someren E, Snoek FJ, Strijers RL, Swaab DF, Visscher F et al. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. J Neurol 1993; 240: 446-448.

57. Iriarte J, Subirá ML, de Castro P. Modalities of multiple sclerosis: correlation with clinical and biological factors. Mult Scler 2000; 6: 124-130.

58. The Canadian MS Research group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14: 273-278.

59. Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol 1988; 45: 1104-1106.

60. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676-680.

61. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996; 53: 185-188.

62. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985; 12: 251-254.

63. Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71-77.

64. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983; 60: 353-362.

65. van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross- over study. Ann Neurol 1992; 32: 123-130.

66. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998; 121: 967-975.

67. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956-1961.

68. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-1471.

69. Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000; 81: 164-169.

70. Di-Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil 1998; 79: 141-146.

71. Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9: 456-460.

72. Stuifbergen AK, Rogers S. The experience of fatigue and strategies of self-care among persons with multiple sclerosis. Appl Nurs Res 1997; 10: 2-10.